Literature DB >> 20195869

Validity of the definite and semidefinite questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I.

Jesper Bent-Hansen1, Per Bech.   

Abstract

Instruments for self-rating in depression are available, but their psychometric properties have not been fully explored; discrepancies with clinician ratings have been identified. This study was longitudinal with 85 patients fulfilling the DSM-III-R diagnosis of Seasonal Affective Disorder. Self-reporting versions (definitely and semidefinitely anchored) corresponding to the Hamilton Depression Scale (HAMD), the Hamilton Subscale (HAM₆), and the Bech-Rafaelsen Melancholia Scale (MES) were compared to each other and the clinician-rated version. The unidimensional property of the sum score in each scale was tested by the item-response theory model ad modum Rasch. The scales were also tested for their sensitivity to discriminate between placebo and citalopram therapy. The sum scores and the sum score variances of the definite self-rating versions did not differ significantly from the sum scores of the corresponding observer scales at any of the five time points. The semidefinite scales significantly over-scored at all time points. The convergent validity between corresponding definite self-ratings and observer ratings was very high with correlations exceeding 0.90. Only item responses from the MES, the HAM₆, and their corresponding definite versions of the self-rating questionnaires DMQ and DHAM₆ were accepted by the Rasch analysis, and only these four valid scales discriminated significantly between the effect of citalopram and placebo treatment. Our results are limited to patients with moderate depression. Two new self-report scales with unparalleled construct validity, reliability, sensitivity, and convergent validity have been identified (DMQ and DHAM₆). We have also identified a crucial importance of format for the means and variances of self-rating scales. These findings are of high practical and scientific value.

Entities:  

Mesh:

Year:  2010        PMID: 20195869     DOI: 10.1007/s00406-010-0106-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  28 in total

1.  Inpatient diagnostic assessments: 1. Accuracy of structured vs. unstructured interviews.

Authors:  P R Miller; R Dasher; R Collins; P Griffiths; F Brown
Journal:  Psychiatry Res       Date:  2001-12-31       Impact factor: 3.222

2.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

3.  Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2001       Impact factor: 5.270

4.  Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes.

Authors:  P Bech; M Kastrup; O J Rafaelsen
Journal:  Acta Psychiatr Scand Suppl       Date:  1986

5.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

6.  Implications of chance baseline differences in repeated measurement designs.

Authors:  J E Overall; S R Doyle
Journal:  J Biopharm Stat       Date:  1994-07       Impact factor: 1.051

Review 7.  The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure.

Authors:  P Bech
Journal:  Acta Psychiatr Scand       Date:  2002-10       Impact factor: 6.392

8.  Comparison between clinician-rated and self-reported depressive symptoms in Italian psychiatric patients.

Authors:  L Tondo; C Burrai; L Scamonatti; J Weissenburger; J Rush
Journal:  Neuropsychobiology       Date:  1988       Impact factor: 2.328

9.  Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems.

Authors:  Stuart J Pocock; Susan E Assmann; Laura E Enos; Linda E Kasten
Journal:  Stat Med       Date:  2002-10-15       Impact factor: 2.373

10.  A definite and a semidefinite questionnaire version of the Hamilton/melancholia (HDS/MES) scale.

Authors:  J Bent-Hansen; L Lauritzen; L Clemmesen; M Lunde; A Kørner
Journal:  J Affect Disord       Date:  1995-03-14       Impact factor: 4.839

View more
  3 in total

1.  The Validity of the WHO-5 as an Early Screening for Apathy in an Elderly Population.

Authors:  Ramona Lucas-Carrasco; Peter Allerup; Per Bech
Journal:  Curr Gerontol Geriatr Res       Date:  2012-09-10

2.  The Pharmacopsychometric Triangle to Illustrate the Effectiveness of T-PEMF Concomitant with Antidepressants in Treatment Resistant Patients: A Double-Blind, Randomised, Sham-Controlled Trial Revisited with Focus on the Patient-Reported Outcomes.

Authors:  P Bech; M Gefke; M Lunde; L Lauritzen; K Martiny
Journal:  Depress Res Treat       Date:  2011-06-07

3.  Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder.

Authors:  Kathryn M Connor; Paulette Ceesay; Jill Hutzelmann; Duane Snavely; Andrew D Krystal; Madhukar H Trivedi; Michael Thase; Christopher Lines; W Joseph Herring; David Michelson
Journal:  Int J Neuropsychopharmacol       Date:  2017-08-01       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.